Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps investors identify effective metrics for assessing momentum in stocks [2] Group 2: Instil Bio, Inc. (TIL) Performance - Instil Bio, Inc. currently holds a Momentum Style Score of A and a Zacks Rank of 2 (Buy), indicating strong potential for outperformance [3][4] - Over the past week, TIL shares have increased by 28.21%, significantly outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by only 0.25% [6] - In a longer timeframe, TIL shares have gained 72.33% over the past quarter and 180.49% over the last year, while the S&P 500 has only moved 2.37% and 14.4%, respectively [7] Group 3: Trading Volume and Earnings Outlook - TIL's average 20-day trading volume is 383,563 shares, which is a bullish indicator when combined with rising stock prices [8] - Recent earnings estimate revisions for TIL show one upward revision for the full year, increasing the consensus estimate from -$8.30 to -$7.71 over the past 60 days [10] - For the next fiscal year, there has been one upward revision with no downward changes, indicating a positive earnings outlook [10] Group 4: Conclusion - Considering all performance metrics and earnings outlook, TIL is positioned as a strong buy candidate with a Momentum Score of A, making it a noteworthy option for investors seeking short-term gains [12]

It has been about a month since the last earnings report for Axsome Therapeutics (AXSM) . Shares have lost about 1.8% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Axsome due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Benitec Biopharma Limited (BNTC) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Benitec Biopharma Limited is a member of our Medical group, which includes 999 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 1 ...

Company Performance - McKesson (MCK) has returned approximately 26.6% since the beginning of the calendar year, outperforming the Medical sector, which has lost about 4.9% on average [4] - McKesson holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, with the consensus estimate for full-year earnings having increased by 1.4% over the past quarter [3] - McKesson belongs to the Medical - Dental Supplies industry, which includes 14 companies and currently ranks 84 in the Zacks Industry Rank, with this group having lost about 1.9% year-to-date [5] Industry Comparison - The Medical sector consists of 999 individual stocks and currently holds a Zacks Sector Rank of 4, which is based on the average Zacks Rank of the individual stocks within the sector [2] - Another stock in the Medical sector, Adagene Inc. Sponsored ADR (ADAG), has a year-to-date return of 4.8% and also holds a Zacks Rank of 2 (Buy), with its consensus EPS estimate increasing by 7.9% over the past three months [4][5] - The Medical - Biomedical and Genetics industry, which includes Adagene, has 503 stocks and is ranked 75, with this industry having moved -2.9% since the beginning of the year [6]

Company Overview - Nurix Therapeutics, Inc. (NRIX) shares increased by 14.2% to close at $12.14, following a period of 5.7% loss over the past four weeks, indicating a significant rebound in stock performance [1][2] Licensing Agreement - Sanofi has exercised its option to exclusively license Nurix's STAT6 program, which includes the development candidate NX-3911, an oral and highly selective STAT6 degrader. Nurix is set to receive a license extension fee of $15 million and is eligible for up to $465 million in potential milestone payments, along with royalties on future sales [2] Financial Expectations - The company is expected to report a quarterly loss of $0.73 per share, reflecting a year-over-year change of -2.8%. Revenue is anticipated to be $17.31 million, representing a 43.2% increase from the same quarter last year [3] Earnings Estimate Revisions - The consensus EPS estimate for Nurix has been revised 1.1% higher over the last 30 days, suggesting a positive trend that may lead to price appreciation in the future [4] Industry Context - Nurix Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Argenx SE (ARGX), saw a 2% increase in its stock price, closing at $584.61, despite a -11.8% return over the past month [4]

Company Performance - Astrazeneca's stock closed at $71.93, reflecting a -1.24% change from the previous day, underperforming the S&P 500 which gained 0.41% [1] - Over the past month, Astrazeneca's shares increased by 0.54%, outperforming the Medical sector's decline of 3.74% but lagging behind the S&P 500's rise of 6.13% [1] Upcoming Earnings - Astrazeneca is expected to report earnings of $1.11 per share, indicating a year-over-year growth of 12.12% [2] - The consensus estimate for quarterly revenue is projected at $14.03 billion, representing an 8.42% increase from the same period last year [2] Full Year Projections - For the full year, earnings are projected at $4.49 per share and revenue at $57.68 billion, showing increases of +9.25% and +6.67% respectively from the previous year [3] - Recent analyst estimate revisions suggest a favorable outlook on Astrazeneca's business health and profitability [3] Valuation Metrics - Astrazeneca's Forward P/E ratio is currently at 16.2, which is lower than the industry average of 20.51 [6] - The company has a PEG ratio of 1.34, compared to the industry average PEG ratio of 1.47 [6] Industry Context - Astrazeneca operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 74, placing it in the top 30% of over 250 industries [7] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $0.85 per share and a separate concurrent private placement of 1,686,275 shares of its ...

Core Insights - Standard BioTools Inc. has launched its inaugural Proteomics Roundtable Series to discuss advancements in the field of proteomics and its implications for healthcare [1] - The first session will focus on high-plex, high-quality proteomics, featuring insights from researchers involved in the EPIC cancer study [2] - Future sessions will cover various topics, including comparative metrics for proteomic platforms, deployment in biobanks, and the role of proteomics in accelerating drug development [3][4][5] Company Overview - Standard BioTools Inc. is a leading provider of next-generation technologies aimed at enhancing biomedical research and drug development [7] - The company utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide reliable insights into health and disease [7] - Standard BioTools collaborates with academic, government, and clinical laboratories globally, focusing on critical areas in translational and clinical research [9]

陕西生化产业技术创新平台有限公司（下称"陕西生化"）及其母公司华森盛邦，凭借在生物医药中 间体及原料、健康食品原料领域的突破性成果，在细分赛道加速前行。 2021年，以董事长翁婧、总经理李蒲民为核心的5人技术骨干开启"二次创业"。他们解决"卡脖 子"技术为使命，构建起"基础研究—中试转化—产业化"的完整链条。他们的白藜芦醇、红景天苷及其 衍生物项目成功入选2024年陕西省重点新产品开发项目，标志着该企业在天然产物提取领域实现关键技 术突破。 在金融机构持续赋能下，这家民营科创企业有望在天然产物提取、合成生物学等前沿领域实现更 多"从0到1"的突破。 编辑：孙庭阳 在华森盛邦的成长轨迹中，长安银行的金融支持堪称关键力量。2024年9月20日，一笔1亿元的固定 资产贷款注入该企业账户，期限长达4年，专项用于科研中心建设及高端研发设备采购。这是陕西生化 成立后获得的首笔贷款。 长安银行通过"长安V+"小微金融品牌矩阵，构建起覆盖近40款产品的立体化服务体系。截至2024 年末，长安银行普惠型小微企业贷款款（不含贴现）余额471亿元，贷款户数达17万户。 在长安银行的战略版图中，华森盛邦案例折射出其服务民营经济的深层 ...

Company Overview - Repligen (RGEN) shares have decreased by approximately 12.2% over the past month, underperforming the S&P 500 [1] - The most recent earnings report is essential to understand the key drivers affecting the stock [1] Earnings Estimates - Estimates for Repligen have trended downward, with a consensus estimate shift of -5.33% in the past month [2] VGM Scores - Repligen has a Growth Score of B, but a low Momentum Score of D, and a Value Score of D, placing it in the bottom 40% for value investment strategy [3] - The overall aggregate VGM Score for Repligen is C, which is relevant for investors not focused on a single strategy [3] Market Outlook - The downward trend in estimates indicates a negative outlook for Repligen, with a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [4] Industry Comparison - Repligen is part of the Zacks Medical - Biomedical and Genetics industry, where Gilead Sciences (GILD) has seen a 1.8% increase in stock price over the past month [5] - Gilead reported revenues of $6.67 billion for the last quarter, reflecting a year-over-year decline of -0.3%, with an EPS of $1.81 compared to -$1.32 a year ago [5] - For the current quarter, Gilead is expected to report earnings of $1.99 per share, indicating a -1% change from the previous year, with a slight estimate change of -0.1% over the last 30 days [6]